THE ROLE OF SYSTEMIC AND LOCAL INFLAMMATION IN DIABETIC NEPHROPATHY
https://doi.org/10.24884/1561-6274-2011-15-4-21-26
Abstract
The article contains analysis of contemporary data on the role of systemic and local inflammation in diabetic nephropathy. Renal effects of proinflammatory cytokines (tumor necrosis factor-α, interleukin-1, interleukin-6, interleukin-18) are described. The main directions of pathogenetic therapy are discussed. Further investigations are needed to elucidate inflammatory mechanisms of renal irritation at diabetes mellitus and prognostic relevance of inflammatory markers in patients with diabetic nephropathy
About the Authors
I. Yu. PCHELIN
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
A. N. SHISHKIN
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
O. A. LAPTEVA
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
References
1. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет 2011; (1): 81-88
2. Jerums G., Premaratne E., Panagiotopoulus S. et al. New and old markers of progression of diabetic nephropathy. Diab Res Clin Pract 2008; 82: 30-37
3. Nosadini R., Tonolo G. Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. J. Am Soc Nephrol 2004; 15 [Suppl 1]: S1-S5
4. Alaveras A.E.G., Thomas S.M., Sagriotis A. et al. Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 71-74
5. Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure independent effect. Circulation 2002; 106: 672-678
6. Karalliedde J., Gnudi L. ACCORD and ADVANCE: A tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 2008; 23: 1796-1798
7. Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
8. Kelly K.J., Domingues J.H. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J. Nephrol 2010; 32: 469-475
9. Kaul K., Hodgkinson A., Tarr J.M. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diab Rev 2010; 6: 294-303
10. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin Endocrinol Metab 2009; 94: 3171-3182
11. Segerer S., Nelson P.J., Schlondorff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic Science to Pathophysiological and Therapeutic Studies. J. Am Soc Nephrol 2000; 11: 152-176
12. Fornoni A., Ijaz A., Tejada T. et al. Role of Inflammation in Diabetic Nephropathy. Curr Diab Rev 2008; 4: 10-17
13. Navarro-Gonzalez J.F., Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy. J. Am Soc Nephrol 2008; 19: 433-442
14. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of TNF-α in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17: 441-450
15. Ray A., Huisman M.V., Tamsma J.T. et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J. Int Med 2009; 20: 253-260
16. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
17. Dandona P., Chaudhuri A. Anti-inflammatory and antiatherogenic effects of Insulin. Insulin 2006; 1 [Suppl 1]: S11-S17
18. Welsh G.I., Hale L.J., Eremina V. et al. Insulin Signaling to the Glomerular Podocyte Is Critical for Normal Kidney Function. Cell Metab 2010; 12: 329-340
19. Hyvonen M.E., Saurus P., Wasik A. et al. Lipid phosphotase SHIP2 downregulates insulin signaling in podocytes. Moll Cell Endorinol 2010; 328: 70-79
20. Siragy H.M., Awad A., Abadir P. et. al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003; 144: 2229-2233
21. Siragy H.M., Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008; 93: 817-824
22. Theilig F. Spread of glomerular to tubulointerstitial disease with a focus on proteinuria. Ann Anat 2010; 192: 125-132
23. Шишкин А.Н. Факторы роста и гломерулосклероз при диабетической нефропатии. Нефрология 2005; 9(4): 104107
24. Li J.H., Huang X.R., Zhu H.-J. et al. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019
25. Nicholas S.B., Liu J., Kim J. et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010; 77: 588-600
26. Yevdokimova N., Wahab N.A., Mason R.M. Thrombospondin-1 Is the Key Activator of TGF-ß1 in Human Mesangial Cells Exposed to High Glucose. J. Am Soc Nephrol 2001; 12: 703-712
27. Navarro-Gonzalez J.F., Mora-Fernandez C., De Fuentes M.M. et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
28. Moriwaki Y., Yamamoto T., Shibutani Y. et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608
29. Zozulinska D., Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 2006; 74 [Suppl 1]: S12-S16
30. Wisse B.E. The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity. J. Am Soc Nephrol 2004; 15: 2792-2800
31. Navarro-Gonzalez J.F., Mora C., Muros M. et al. Urinary tumor necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006; 21: 34283434
32. Navarro-Gonzalez J.F., Mora C., Macia M. et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J. Kidney Dis 2003; 42 [Suppl 2]: 53-61
33. Dalla Vestra M., Mussap M., Gallina P. et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am Soc Nephrol 2005; 16 [Suppl 1]: S78-S82
34. Nakamura A., Shikata K., Hiramatsu M. et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895
35. Aso Y., Yosida N., Okumura K. et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348: 139-145
36. Jacobsen P., Tarnow L., Carstensen B. et al. Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy. J. Am Soc Nephrol 2003; 14: 2843-2850
37. Lind L. Circulating markers of inflammation and Atherosclerosis. Atherosclerosis 2003; 169: 203-214
38. Raj D.S.C. Role of Interleukin-6 in the Anemia of Chronic Disease. Semin Arthritis Rheum 2009; 38: 382-388
39. Lankhorst C.E., Wish J.B. Anemia in renal disease: Diagnosis and management. Blood Rev 2010; 24: 39-47
40. Buck I., Morceau F., Grigorakaki C. et al. Linking anemia to inflammation and cancer: The crucial role of TNF-α. Biochem Pharmacol 2009; 77: 1572-1579
41. Пчелин И.Ю., Шишкин А.Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн. С.-Петерб. ун-та. Сер. 11 2010; (2): 73-80
42. Silverberg D., Wexler D. Anemia, the fifth major cardiovascular risk factor. Transfus Med Hemotherapy 2004; 31: 175-179
43. Keane W.F., Brenner B.M., De Zeeuw D. et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003; 63: 1499-1507
44. Garcia C., Feve B., Ferre P. et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab 2010; 36: 327-338
45. Navarro-Gonzalez J.F., Jarque A., Muros M. et al. Tumor necrosis factor-α as a target for diabetic nephropathy. Cytokine Growth Factor Rev 2009; 20: 165-173
46. Raval G., Mehta P. TNF-α inhibitors: Are they carcinogenic? Drug Health Patient Saf 2010; 2: 241-247
47. Leyva-Jimenez R., Rodrigues-Orozco.AR., Ortega-Pierres L.E. et al. Effect of pentoxifylline on the evolution of diabetic nephropathy. Med Clin 2009; 132: 772-778
48. McCormick B.B., Sydor A., Akbari A. et al. The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Diasease: A Meta-analysis. а 2008; 52: 454-463
49. Navarro-Gonzalez J.F., Milena F.G., Mora C. et al. Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005; 68 [Suppl 99]: S98-S102
50. Navarro-Gonzalez J.F., Mora C., Muros M. et al. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am Soc Nephrol 2005; 16: 21192126
51. Manning P.G., Sutherland W.H.F., Walker R.J. et al. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res Clin Pract 2008; 81: 209-215
52. Zheng M., Ye S., Zhai Z. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J. Diabetes Complications 2009; 23: 124-129
53. Sarafidis P.A., Stafylas P.C., Georgianos P.I. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. Am J. Kidney Dis 2010; 55: 835-847
54. Kostapanos M.S., Liberopoulos E.N., Elisaf M.S. Statin pleiotropy against renal injury. J. Cardiometab Syndr 2009; 4: 4-9
55. Campese V.M., Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71: 1215-1222
56. Balakumar P., Arora M.K., Ganti S.S. et al. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol Res 2009; 60: 24-32
57. Danis R.P., Sheetz M.J. Ruboxistaurin: PKC-β inhibition for complications of diabetes. Expert Opin Pharmacother 2009; 10: 2913-2925
Review
For citations:
PCHELIN I.Yu., SHISHKIN A.N., LAPTEVA O.A. THE ROLE OF SYSTEMIC AND LOCAL INFLAMMATION IN DIABETIC NEPHROPATHY. Nephrology (Saint-Petersburg). 2011;15(4):21-26. (In Russ.) https://doi.org/10.24884/1561-6274-2011-15-4-21-26
Views:
381
Email this article 